DexCom (DXCM)
(Real Time Quote from BATS)
$135.36 USD
-2.51 (-1.82%)
Updated Apr 25, 2024 10:46 AM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
DXCM 135.36 -2.51(-1.82%)
Will DXCM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DXCM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DXCM
Wall Street Bulls Look Optimistic About DexCom (DXCM): Should You Buy?
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
DXCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ahead of DexCom (DXCM) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Zacks Investment Ideas feature highlights: Vertiv, Align Technology and DexCom
3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback
Other News for DXCM
DexCom Q1 2024 Earnings Preview
Top high growth investment ratio stocks from each sector - GS
3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback
First Week of December 20th Options Trading For DexCom (DXCM)
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom